It is authorized by primary peptides, Inc. in China to develop and sell innovative drugs targeting PTEN for the treatment of stroke

Yabao Pharmaceutical (Shanghai Securities: 600351) announced on September 15, 2015 that it was authorized by primary peptides, Inc. in China to develop and sell innovative drugs targeting PTEN for the treatment of stroke.
Under the terms of the agreement, Albo has the right to develop and sell Chinese mainland, Taiwan and Hongkong, and Primary Peptides reserves the right to other markets. Financial terms are not disclosed.
Dr. Wang Peng, R & D president of Yabao pharmaceutical, said: "Yabao is very pleased to cooperate with primary peptides in peptide therapy in the field of cardiovascular and neuroscience. This is an opportunity for Yabao to expand the research and development of innovative products and further evidence of Yabao's increasing commitment to using science and technology to treat serious diseases in China."
Dr. Max cynader of primary peptides said: "we are pleased to combine our expertise in the early research and development of innovative drugs with the important resources brought by Yabao pharmaceutical to jointly develop breakthrough innovative drugs. There is a large gap in medical demand for stroke protection, and this new polypeptide treatment is expected to improve the quality of life of many stroke patients. “
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) As a Chinese pharmaceutical enterprise, Yabao has perfect capabilities in drug development, production and commercialization in China. Recently, Yabao has adjusted its strategic development direction and aimed at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities, and the production of preparations and APIs meets the quality management of drug production CGMP requirements and passed the inspection of FDA and EU drug regulatory authorities respectively.
About primary peptides
Primary peptides is a biotechnology company that has developed a proprietary platform technology that enables it to identify, target and destroy specific protein-protein interactions, leading to the medical needs of new polypeptide therapies. Primary peptides can also replace siRNA in many indications and improve pharmacokinetics and specificity. Primary peptides are used in several neurological and cardiovascular indications Lead compounds are developed in.

Next:The second strategic cooperation with Eli Lilly has jointly developed the sodium glucose co transporter (SGLT1) molecule for the treatment of diabetes.